Making medications safer for newborns

Although new drugs must be shown to be both safe and effective for approval by the Food and Drug Administration, sick newborns receive most of their drug treatment off-label and without the evidence provided for adults and older children.

A new editorial looks at the challenges of performing clinical trials in newborns, from the reluctance of parents to enroll their infants to the lack of experience of pediatricians and neonatologists in conducting clinical research.

Fortunately, new efforts to increase the study of drugs in newborns and to improve the efficiency of these studies are underway.

"We can look to a future when neonatal drug therapy has the same solid data base that is provided for treatment of and adults," wrote the authors of the British Journal of Clinical Pharmacology editorial.


Explore further

Adverse drug reactions may be under-reported in young children

More information: Newborns still lack drug data to guide therapy. DOI: 10.1111/bcp.13074
Provided by Wiley
Citation: Making medications safer for newborns (2016, October 4) retrieved 19 August 2019 from https://medicalxpress.com/news/2016-10-medications-safer-newborns.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more